Jump to section
BioIntelliSense's mission is to create a healthier, more informed population and improve clinical outcomes.
70% employee growth in 12 months
BioIntelliSense’s data-as-a-service platform offers continuous health monitoring and clinical intelligence services. Using the company’s pair of FDA-cleared devices, clinicians can access high-resolution patient data from outside clinical settings, helping them deliver high quality medical care across different environments.
BioIntelliSense is getting in on a market expected to see impressive growth: the remote patient monitoring market is anticipated to hit almost $120 billion globally by just 2025. This promising market, however, has brought along with it a flurry of rival and well-funded startups like Huma, Biofourmis, and TytoCare. FDA approval for their devices offers BioIntelliSense an edge in some cases - but it is an edge it will need to defend as other providers catch up.
Playing generally in the company’s favor is the increasing trend towards telehealth services - especially with moves being made in congress to expand the use of telehealth for programmes like Medicaid and Medicare Advantage. It looks like remote monitoring will fast become a mainstay of healthcare, and BioIntelliSense’s FDA-approved offerings put the company in good stead to net strong growth from this.
Kirsty
Company Specialist at Welcome to the Jungle
Jul 2021
$45m
SERIES B
Sep 2020
$12m
EARLY VC
James Mault
(CEO & Chairman)James studied Medicine at the University of Michigan before working as a Cardiothoracic surgeon and founding HealtheTech in 1998 and working as CEO of Microlife Health Solutions. They worked at Microsoft and Qualcomm, leaving the latter in June 2018 to co-found BioIntelliSense.
David Wang
(CTO)Having studied Electrical Engineering and Management Science at Stanford, David worked as a Cisco Engineer and research Assistant at Berkeley Wireless Research Center. After roles at Centrality Communications, SiRF, Booyah, and Striiv, they co-founded BioIntelliSense in 2018 with James.